{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T11:30:03Z","timestamp":1785583803105,"version":"3.56.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"funder":[{"name":"Medizinische Hochschule Hannover (MHH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n          <jats:p>Rituximab (RTX) bewirkt durch Bindung an das CD20-Antigen eine B\u2011Zell-Depletion. Eine weniger bekannte unerw\u00fcnschte Arzneimittelwirkung von RTX ist die ca. 6\u00a0Monate nach Therapiebeginn auftretende Late-onset-Neutropenie (LON). Als klinisches Management sollten unter RTX-Therapie regelm\u00e4\u00dfige Differenzialblutbildkontrollen erfolgen. Bei akuten LON-Episoden kann neben einer Watch-and-Wait-Strategie eine unterst\u00fctzende Gabe von G\u2011CSF (\u201egranulocyte colony-stimulating factor\u201c) diskutiert werden. Die Reexposition mit RTX nach stattgehabter LON wird nach Abw\u00e4gung von Risikofaktoren und ausf\u00fchrlicher Aufkl\u00e4rung im Allgemeinen als vertretbar erachtet. In dieser Fallserie m\u00f6chten wir 2\u00a0F\u00e4lle von rheumatologischen Patienten mit schwerwiegender LON nach RTX-Gabe vorstellen.<\/jats:p>","DOI":"10.1007\/s00393-025-01668-2","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T12:00:08Z","timestamp":1749038408000},"page":"667-670","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Schwerwiegende Late-onset-Neutropenien nach Rituximab-Gabe","Severe late-onset neutropenia after rituximab administration"],"prefix":"10.1007","volume":"84","author":[{"given":"Carla E.","family":"Sch\u00fctte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Hillebrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens G.","family":"Kuipers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk O.","family":"Stichtenoth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick-Pascal","family":"Strunz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Heck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,4]]},"reference":[{"issue":"4","key":"1668_CR1","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1179\/1607845414Y.0000000188","volume":"20","author":"Y Arai","year":"2015","unstructured":"Arai\u00a0Y, Yamashita\u00a0K, Mizugishi\u00a0K et\u00a0al (2015) Risk factors for late-onset neutropenia after rituximab treatment of B\u2011cell lymphoma. Hematology 20(4):196\u2013202","journal-title":"Hematology"},{"issue":"6","key":"1668_CR2","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.anai.2023.01.018","volume":"130","author":"TS Athni","year":"2023","unstructured":"Athni\u00a0TS, Barmettler\u00a0S (2023) Hypogammaglobulinemia, late-onset neutropenia, and infections following rituximab. Ann Allergy Asthma Immunol 130(6):699\u2013712","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"1668_CR3","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1177\/13524585231206218","volume":"30","author":"Y Beigneux","year":"2024","unstructured":"Beigneux\u00a0Y, Louapre\u00a0C, Bihan\u00a0K et\u00a0al (2024) Recurrence of severe symptomatic late-onset neutropenia on ocrelizumab. Mult Scler 30(1):131\u2013133","journal-title":"Mult Scler"},{"issue":"6","key":"1668_CR4","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1093\/qjmed\/hcs015","volume":"105","author":"E Besada","year":"2012","unstructured":"Besada\u00a0E, Koldingsnes\u00a0W, Nossent\u00a0J (2012) Characteristics of late onset neutropenia in rheumatologic patients treated with rituximab: a\u00a0case review analysis from a\u00a0single center. QJM 105(6):545\u2013550","journal-title":"QJM"},{"issue":"9","key":"1668_CR5","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1007\/s10067-014-2562-x","volume":"33","author":"GS Breuer","year":"2014","unstructured":"Breuer\u00a0GS, Ehrenfeld\u00a0M, Rosner\u00a0I et\u00a0al (2014) Late-onset neutropenia following rituximab treatment for rheumatologic conditions. Clin Rheumatol 33(9):1337\u20131340","journal-title":"Clin Rheumatol"},{"issue":"4 Pt 2","key":"1668_CR6","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/pr.2011.57","volume":"71","author":"T Daikeler","year":"2012","unstructured":"Daikeler\u00a0T, Tichelli\u00a0A, Passweg\u00a0J (2012) Complications of autologous hematopoietic stem cell transplantation for patients with autoimmune diseases. Pediatr Res 71(4 Pt 2):439\u2013444","journal-title":"Pediatr Res"},{"issue":"1","key":"1668_CR7","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s00393-024-01611-x","volume":"84","author":"M Gernert","year":"2025","unstructured":"Gernert\u00a0M, Schwaneck\u00a0EC, Schmalzing\u00a0M (2025) \u201eT-large granular lymphocytic\u201c-Leuk\u00e4mie und Felty-Syndrom bei rheumatoider Arthritis. Z\u00a0Rheumatol 84(1):48\u201356","journal-title":"Z Rheumatol"},{"issue":"12","key":"1668_CR8","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1007\/s00115-023-01507-2","volume":"94","author":"F Hess","year":"2023","unstructured":"Hess\u00a0F, Uibel\u00a0P, Berthele\u00a0A, Hemmer\u00a0B (2023) Ocrelizumab-assoziierte schwere Neutropenie: eine untersch\u00e4tzte Komplikation der Therapie mit CD20-Antik\u00f6rpern bei Multipler Sklerose? Nervenarzt 94(12):1153\u20131156","journal-title":"Nervenarzt"},{"issue":"10","key":"1668_CR9","first-page":"1162","volume":"18","author":"C Hosp","year":"2020","unstructured":"Hosp\u00a0C, Goebeler\u00a0M, Benoit\u00a0S, Stoevesandt\u00a0J (2020) Rituximab-induzierte, verz\u00f6gert auftretende Neutropenie bei blasenbildenden Autoimmunerkrankungen: harmlos oder untersch\u00e4tzte Gefahr? J\u00a0Dtsch Dermatol Ges 18(10):1162\u20131164","journal-title":"J Dtsch Dermatol Ges"},{"issue":"10","key":"1668_CR10","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1007\/s10067-016-3313-y","volume":"35","author":"WE Monaco","year":"2016","unstructured":"Monaco\u00a0WE, Jones\u00a0JD, Rigby\u00a0WFC (2016) Rituximab associated late-onset neutropenia\u2014a rheumatology case series and review of the literature. Clin Rheumatol 35(10):2457\u20132462","journal-title":"Clin Rheumatol"},{"issue":"9","key":"1668_CR11","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1177\/0961203318777116","volume":"27","author":"I Parodis","year":"2018","unstructured":"Parodis\u00a0I, S\u00f6der\u00a0F, Faustini\u00a0F et\u00a0al (2018) Rituximab-mediated late-onset neutropenia in systemic lupus erythematosus\u2014distinct roles of BAFF and APRIL. Lupus 27(9):1470\u20131478","journal-title":"Lupus"},{"issue":"3","key":"1668_CR12","doi-asserted-by":"publisher","first-page":"100529","DOI":"10.1016\/j.medj.2024.10.006","volume":"6","author":"M Protopapa","year":"2025","unstructured":"Protopapa\u00a0M, Schraad\u00a0M, Pape\u00a0K et\u00a0al (2025) Recurrent late-onset neutropenia following treatment with different B\u00a0cell-depleting strategies in multiple sclerosis. Med 6(3):100529","journal-title":"Med"},{"issue":"1","key":"1668_CR13","doi-asserted-by":"publisher","first-page":"e000034","DOI":"10.1136\/rmdopen-2014-000034","volume":"1","author":"JH Salmon","year":"2015","unstructured":"Salmon\u00a0JH, Cacoub\u00a0P, Combe\u00a0B et\u00a0al (2015) Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the AutoImmunity and Rituximab registry. RMD Open 1(1):e34. https:\/\/doi.org\/10.1136\/rmdopen-2014-000034","journal-title":"RMD Open"},{"issue":"12","key":"1668_CR14","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1080\/10428194.2021.1948037","volume":"62","author":"S Shimony","year":"2021","unstructured":"Shimony\u00a0S, Bar-Sever\u00a0E, Berger\u00a0T et\u00a0al (2021) Late onset neutropenia after rituximab and obinutuzumab treatment\u2014characteristics of a\u00a0class-effect toxicity. Leuk Lymphoma 62(12):2921\u20132927","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"1668_CR15","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1097\/MD.0b013e3181f2caef","volume":"89","author":"O Wolach","year":"2010","unstructured":"Wolach\u00a0O, Bairey\u00a0O, Lahav\u00a0M (2010) Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature. Med 89(5):308\u2013318","journal-title":"Med"},{"issue":"2","key":"1668_CR16","first-page":"494","volume":"20","author":"X Zhang","year":"2022","unstructured":"Zhang\u00a0X, Rao\u00a0M, Xu\u00a0G (2022) An update on the incidence, risk factors and mechanisms of rituximab-associated neutropenia. Arch Med Sci 20(2):494\u2013505","journal-title":"Arch Med Sci"},{"issue":"2","key":"1668_CR17","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/art.41501","volume":"73","author":"R Zonozi","year":"2021","unstructured":"Zonozi\u00a0R, Wallace\u00a0ZS, Laliberte\u00a0K et\u00a0al (2021) Incidence, Clinical Features, and Outcomes of Late-Onset Neutropenia From Rituximab for Autoimmune Disease. Arthritis Rheumatol 73(2):347\u2013354","journal-title":"Arthritis Rheumatol"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-025-01668-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-025-01668-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-025-01668-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T10:06:28Z","timestamp":1759313188000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-025-01668-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,4]]},"references-count":17,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1668"],"URL":"https:\/\/doi.org\/10.1007\/s00393-025-01668-2","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,4]]},"assertion":[{"value":"2 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"C.E.\u00a0Sch\u00fctte, C.\u00a0Hillebrecht, J.G.\u00a0Kuipers, D.O.\u00a0Stichtenoth, P.-P.\u00a0Strunz und J.\u00a0Heck geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine interventionellen Studien an Menschen oder Tieren. Einverst\u00e4ndniserkl\u00e4rungen der in den Kasuistiken dargestellten Patienten f\u00fcr die Nutzung patientenbezogener Daten im Rahmen dieser Publikation liegen vor. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}